U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H26N2O3.ClH
Molecular Weight 342.861
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROXATIDINE HYDROCHLORIDE

SMILES

Cl.OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

InChI

InChIKey=DPCZALPCMCPHAK-UHFFFAOYSA-N
InChI=1S/C17H26N2O3.ClH/c20-14-17(21)18-8-5-11-22-16-7-4-6-15(12-16)13-19-9-2-1-3-10-19;/h4,6-7,12,20H,1-3,5,8-11,13-14H2,(H,18,21);1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C17H26N2O3
Molecular Weight 306.3999
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.drugsupdate.com/generic/view/456/Roxatidine | https://www.ncbi.nlm.nih.gov/pubmed/1717223 | https://www.ncbi.nlm.nih.gov/pubmed/20718616

Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: Small amounts of roxatidine were detectable in the CSF, the CSF to plasma ratio ranging from 0 to 0.89.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8429
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8429
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8429
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8429
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
PubMed

PubMed

TitleDatePubMed
Histamine H2-receptor antagonistic action of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)acetoxyacetamide hydrochloride (TZU-0460).
1985
Penetration of roxatidine into the cerebrospinal fluid.
1988
Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
1991 Aug
Roxatidine, an H(2) receptor blocker, is an estrogenic compound--experimental evidence.
2010 Aug
Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation.
2017 Jan 31
Patents

Patents

JP2011157298
4
JPH06271467A
4

Sample Use Guides

In Vivo Use Guide
Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime. Gastro-oesophageal reflux disease: 75 mg bid or 150 mg at bedtime for 6-8 weeks. Gastritis: 75 mg once daily in the evening. Zollinger-Ellison syndrome: 75 mg bid. Premedication before anaesthesia: 75 mg in the evening on the day before surgery and repeated 2 hours before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery. Intravenous Upper gastrointestinal haemorrhage: 75 mg bid via slow injection or infusion.
Route of Administration: Other
In Vitro Use Guide
6.25-25 uM Roxatidine suppressed the PMACI-induced production of pro-inflammatory cytokines in HMC-1
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:06:51 GMT 2023
Edited
by admin
on Fri Dec 15 18:06:51 GMT 2023
Record UNII
8MN79F61ZI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROXATIDINE HYDROCHLORIDE
Common Name English
HOE-062
Code English
ACETAMIDE, 2-HYDROXY-N-(3-(3-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
ROXATIDINE HCL
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID80913548
Created by admin on Fri Dec 15 18:06:51 GMT 2023 , Edited by admin on Fri Dec 15 18:06:51 GMT 2023
PRIMARY
CAS
97900-88-4
Created by admin on Fri Dec 15 18:06:51 GMT 2023 , Edited by admin on Fri Dec 15 18:06:51 GMT 2023
PRIMARY
PUBCHEM
178998
Created by admin on Fri Dec 15 18:06:51 GMT 2023 , Edited by admin on Fri Dec 15 18:06:51 GMT 2023
PRIMARY
FDA UNII
8MN79F61ZI
Created by admin on Fri Dec 15 18:06:51 GMT 2023 , Edited by admin on Fri Dec 15 18:06:51 GMT 2023
PRIMARY
Related Record Type Details
Structure of ROXATIDINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ROXATIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966